To view this email as a web page,
click here Breaking News | | | Thursday, July 27, 2017 One of AstraZeneca’s big hopes, a combination of its new immuno-oncology drug and another experimental cancer drug, has missed a key primary endpoint in first-line lung cancer patients. |
|
|
| | | Thursday, July 27, 2017 Will Mystic make it? That’s been the pressing question for AstraZeneca for months as the lung cancer trial proceeded. Answer: It didn’t, at least not yet. And it’s not just AZ's rep riding on that news, because Mystic was seen as a scrying glass of sorts. It would foretell which cancer cocktails would dominate over the next few years. |
|
|
|
|
.
